Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | PTPRC | P08575 | 1/20 | 0.30 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.30 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.30 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.30 |
| ▸ | CCR9 | P51686 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25569848 | 0.79 | CHRNA7 (0.34) | AAK1PAX8OPRM1OPRK1MRGPRX4 | |
| SCHEMBL25569912 | 0.79 | CHRNA7 (0.34) | AAK1PAX8OPRM1OPRK1MRGPRX4 | |
| SCHEMBL25569913 | 0.79 | CHRNA7 (0.34) | AAK1PAX8OPRM1OPRK1MRGPRX4 | |
| SCHEMBL25569868 | 0.78 | OPRM1 (0.38) | AAK1PAX8OPRM1OPRK1MRGPRX4 | |
| SCHEMBL25569886 | 0.78 | OPRM1 (0.38) | AAK1PAX8OPRM1OPRK1MRGPRX4 | |
| SCHEMBL25569892 | 0.78 | OPRM1 (0.38) | AAK1PAX8OPRM1OPRK1MRGPRX4 | |
| SCHEMBL3962061 | 0.75 | PAX8 (0.47) | PAX8OPRM1OPRK1MRGPRX4 | |
| SCHEMBL30430045 | 0.71 | PTPRC (0.33) | PTPRCPTPN6PTPN11PTPN22 | |
| SCHEMBL25672258 | 0.71 | PTPRC (0.33) | PTPRCPTPN6PTPN11PTPN22 | |
| SCHEMBL25569902 | 0.71 | CTNNB1 (0.40) | AAK1PAX8PTPRCPTPN6PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | SLC6A3, CREBBP, SLC1A2 | AAK1 1692/4885PAX8 1892/4885OPRM1 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.